Development and characterization of surface engineered PPI dendrimers for targeted drug delivery
Source abstract
Abstract
In this study, we reported folate-conjugated polypropylene imine dendrimers (FA-PPI) as efficient carrier for model anticancer drug, methotrexate (MTX), for pH-sensitive drug release, selective targeting to cancer cells, and anticancer activity. In the in vitro drug release studies this nanoconjugate of MTX showed initial rapid release followed by gradual slow release, and the drug release was found to be pH sensitive with greater release at acidic pH. The ex vivo investigations with human breast cancer cell lines, MCF-7, showed enhanced cytotoxicity of MTX-FA-PPI with significantly enhanced intracellular uptake. The biofate of nanoconjugate was determined in Wistar rat where MTX-FA-PPI showed 37.79-fold increase in the concentration of MTX in liver after 24 h in comparison with free MTX formulation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy, Moga, Punjab, India;
National Institute of Pharmaceutical Education and Research (NIPER Raebareli), Raebareli, Uttar Pradesh, India;
Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A & M Health Science Center, Texas A & M University, Kingsville, TX, USA;
School of Pharmaceutical Sciences, Rajiv Gandhi Technical University, Bhopal, Madhya Pradesh, India
References (35)
Show source-provided references
1. 10.1016/j.ijpharm.2013.08.03710.1016/j.ijpharm.2013.08.037 ↗
2. 10.3109/21691401.2015.105246810.3109/21691401.2015.1052468 ↗
3. 10.3390/ijms15091707710.3390/ijms150917077 ↗
4. 10.1016/j.proeng.2013.02.08810.1016/j.proeng.2013.02.088 ↗
5. 10.1002/anie.19931308110.1002/anie.199313081 ↗
6. 10.1021/ac401377n10.1021/ac401377n ↗
7. 10.1016/j.ejps.2012.12.02710.1016/j.ejps.2012.12.027 ↗
8. 10.1016/j.ijpharm.2010.04.00210.1016/j.ijpharm.2010.04.002 ↗
9. 10.7150/thno.726610.7150/thno.7266 ↗
10. 10.1155/2013/24383110.1155/2013/243831 ↗
11. 10.1007/s11051-013-2003-910.1007/s11051-013-2003-9 ↗
12. 10.1016/j.ejpb.2014.03.01510.1016/j.ejpb.2014.03.015 ↗
13. 10.1016/j.drudis.2013.08.00510.1016/j.drudis.2013.08.005 ↗
14. 10.1166/jnn.2014.867710.1166/jnn.2014.8677 ↗
15. 10.1016/j.jim.2015.03.01710.1016/j.jim.2015.03.017 ↗
16. 10.1016/j.ijpharm.2010.04.02710.1016/j.ijpharm.2010.04.027 ↗
17. 10.2174/138161282166615090110320810.2174/1381612821666150901103208 ↗
18. 10.1128/AAC.04213-1410.1128/AAC.04213-14 ↗
19. 10.1016/j.nano.2014.11.00810.1016/j.nano.2014.11.008 ↗
20. 10.1016/j.progpolymsci.2013.07.00510.1016/j.progpolymsci.2013.07.005 ↗
21. 10.1016/j.ejmech.2011.11.02710.1016/j.ejmech.2011.11.027 ↗
22. 10.1021/bc300025d10.1021/bc300025d ↗
23. 10.1016/j.addr.2010.09.00310.1016/j.addr.2010.09.003 ↗
24. 10.1016/j.drudis.2015.01.00610.1016/j.drudis.2015.01.006 ↗
25. 10.1039/c2cs15294k10.1039/c2cs15294k ↗
26. 10.1016/j.biomaterials.2008.04.03810.1016/j.biomaterials.2008.04.038 ↗
27. 10.1517/17425247.2015.97454610.1517/17425247.2015.974546 ↗
28. 10.1016/j.bmc.2011.04.04610.1016/j.bmc.2011.04.046 ↗
29. Sharma P · Curr Drug Deliv · 2015
30. 10.1021/bc800125u10.1021/bc800125u ↗
31. 10.1021/mp300560n10.1021/mp300560n ↗
32. Thakur S · Polymer · 2015 · 12 · 612
33. 10.1021/mp300223210.1021/mp3002232 ↗
34. 10.1016/j.actbio.2015.01.02110.1016/j.actbio.2015.01.021 ↗
35. 10.1158/1535-7163.MCT-05-032510.1158/1535-7163.MCT-05-0325 ↗